Trelagliptin Size:Solid 2 mg 3(3):599-610

3(3):599-610

1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion

33(5):332-353

INCB 14943

6S)-4-amino-5-hydroxy-4

Trelagliptin Size:Solid 2 mg 3(3):599-610Trelagliptin, also known as SYR 472, is a long acting dipeptidyl peptidase 4 (DPP 4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D). Once weekly SYR 472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin (Zafatek()) was approved in